Alkermes stock
ALKSNASDAQAlkermes plc, HealthcareISIN IE00B56GVS15
53Score 53 out of 100, Neutral
Price and trend
83 / 100
Price history
+42% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 17% above it.
Since January 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 71).
The price is 13% below its 52-week high. Largest decline in 20 years: 84% (December 2015 to March 2020).
Chart figures for advanced users
- SMA 50$43.68
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$41.00
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)71
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$27.20
- The lowest closing price of the last twelve months.
- Resistance$55.22
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Alkermes plc belongs to the Drug Manufacturers (Specialty & Generic) industry (Ireland) and, with a market value of $8.05B, is number 33 of 78 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.48B (down 5.2% year on year) and earnings of $241.66M (down 34.2%).
- For fiscal 2026, analysts expect on average revenue of $1.83B (up 23.8%) and adjusted earnings per share of −$0.53.
Show more
- MEQIRI Score 53 out of 100 (Neutral): rank 353 of 714 in Healthcare, median 53.
- Our model puts fair value at $32.55, with the price 47% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 31% in fiscal 2025, Drug Manufacturers (Specialty & Generic) median 7%.
Weaknesses
- Loss-makingLoss of $351K over the last 12 months.Fundamentals 25
Its standout strengths are momentum and technical analysis, while valuation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
- price up very strongly over the past year
What lowers it
- stable momentum
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $23.25 and expensive above $54.24 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $26.64, at 7.8% it would be $41.43.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 15.3% on the twelve months before. Revenue has grown solidly since 2005, at about 10% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 87%, operating 17%, net 16%. Last 12 months: net 0%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 3 Nov 2026EPS reported $0.09 (expected −$0.08)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 7.7% since 15 Oct 2026.
- Earnings per share
- −$0.53+0.1%
- Revenue
- $1.83B+0.4%
- Earnings per share
- $0.58+7.7%
- Revenue
- $1.93B+0.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −8.3%All sales guidance reiterated, for example VIVITROL $460 million to $480 million; only net loss and EBITDA adjusted due to a fair value effect.
“For the full year, we continue to expect VIVITROL net sales for 2026 in the range of $460 million to $480 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 28 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 6 insiders sold, $5.66M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Gaffin David JosephSale
3 Nov 2026, EVP, CLO, Alkermes, Inc.
- Shares
- 2,035
- Price
- $46.17
- Value
- $93,956
- Gaffin David JosephSale
2 Oct 2026, EVP, CLO, Alkermes, Inc.
- Shares
- 2,034
- Price
- $41.03
- Value
- $83,455
- Gaffin David JosephSale
3 Sept 2026, EVP, CLO, Alkermes, Inc.
- Shares
- 2,034
- Price
- $48.01
- Value
- $97,652
Show 11 more
- Hopkinson Craig C.Sale
1 Sept 2026, EVP R&D, Chief Medical Officer
- Shares
- 9,000
- Price
- $46.99
- Value
- $422,874
- Nichols Christian ToddSale
17 Aug 2026, SVP, Chief Commercial Officer
- Shares
- 7,576
- Price
- $49.23
- Value
- $372,937
- snyderman nancy lynn MDSale
3 Aug 2026, Board
- Shares
- 44,472
- Price
- $50.35
- Value
- $2.24M
- Hopkinson Craig C.Sale
3 Aug 2026, EVP R&D, Chief Medical Officer
- Shares
- 9,000
- Price
- $48.58
- Value
- $437,220
- Gaffin David JosephSale
3 Aug 2026, EVP, CLO, Alkermes, Inc.
- Shares
- 2,034
- Price
- $48.58
- Value
- $98,812
- Gaffin David JosephSale
6 Jul 2026, EVP, CLO, Alkermes, Inc.
- Shares
- 2,034
- Price
- $54.03
- Value
- $109,897
- Hopkinson Craig C.Sale
1 Jul 2026, EVP R&D, Chief Medical Officer
- Shares
- 9,000
- Price
- $51.51
- Value
- $463,621
- Wright Christopher ISale
12 Jun 2026, Board
- Shares
- 2,000
- Price
- $45.10
- Value
- $90,200
- Gaffin David JosephSale
4 Jun 2026, EVP, CLO, Alkermes, Inc.
- Shares
- 2,034
- Price
- $43.05
- Value
- $87,564
- Hopkinson Craig C.Sale
1 Jun 2026, EVP R&D, Chief Medical Officer
- Shares
- 9,000
- Price
- $41.67
- Value
- $375,044
- Parisi Samuel JosephSale
29 May 2026, VP, Finance (Interim PAO)
- Shares
- 16,217
- Price
- $42.36
- Value
- $687,007
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Alkermes
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 53
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- H. LundbeckHLUN-B.CO $9.07B79
- Eisai4523.T $8.91B61
- Krka, d. d.KRK.WA $8.17B74
- Glenmark PharmaceuticalsGLENMARK.NS $8.06B74
- Amneal PharmaceuticalsAMRX $7.56B57
- Huadong Medicine000963.SZ $6.98B62
- Alkem LaboratoriesALKEM.NS $6.95B65
- Lantheus HoldingsLNTH $6.64B76
ETFs that hold Alkermes
Held by 16 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.73% | 0.40% | €1.49B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.52% | 0.30% | €185.82M |
| iShares Ageing Population UCITS ETF2B77 | 0.51% | 0.40% | €807M |
Show 5 more
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.49% | 0.35% | €1.21B |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.43% | 0.30% | €2.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.26% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.26% | 0.30% | €4.22B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.15% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 8 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.